Skip to Main Content
Contribute Try STAT+ Today

Good morning, everyone, and welcome to another working week. We hope the extended weekend break — on our side of the pond, anyway — was somehow relaxing and invigorating, despite the challenging coronavirus news. This was predictable, though, yes? In any event, a new cycle of online calls and deadlines await, so we are coping by engaging in the usual ritual — brewing cups of stimulation. Our choice today is the seasonal peppermint mocha. Feel free to join us. Meanwhile, here is the latest line up of items for you to peruse and digest. We hope you have a smashing day and conquer the world. And of course, do keep in touch. We cherish your private notes and juicy tips. …

Vaccine makers will spend several weeks assessing the danger and potential impact of the new Omicron variant of Covid-19, but they are already racing to develop ways to combat it, The Wall Street Journal explains. For now, researchers at the vaccine companies say it is too early to determine a course of action. Over the next few weeks, they will watch to see if infections from the new variant lead to a surge in hospitalizations and deaths, a sign that Omicron is more dangerous than previous coronavirus variants. Vaccine companies are also awaiting data from lab tests under way to see if existing vaccines generate sufficient neutralizing antibodies to combat the new variant.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment